Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Seattle Genetics Inc (SGEN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 9,297,004
  • Shares Outstanding, K 141,550
  • Annual Sales, $ 418,150 K
  • Annual Income, $ -140,110 K
  • 36-Month Beta 2.25
  • Price/Sales 22.17
  • Price/Book 14.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.17 +16.93%
on 01/30/17
66.64 -1.44%
on 02/16/17
+6.89 (+11.72%)
since 01/20/17
3-Month
50.65 +29.67%
on 01/05/17
72.75 -9.72%
on 11/22/16
-6.45 (-8.94%)
since 11/21/16
52-Week
28.32 +131.92%
on 02/24/16
75.36 -12.85%
on 11/10/16
+35.25 (+115.84%)
since 02/19/16

Most Recent Stories

More News
Immunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients With Metastatic Urothelial Cancer

Phase 2 Results Reported at 2017 Genitourinary (GU) Cancers Symposium

SGEN : 65.68 (+0.27%)
IMMU : 5.06 (-5.24%)
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 - SGEN

The following statement is being issued by Levi & Korsinsky, LLP:

SGEN : 65.68 (+0.27%)
SGEN NOTICE: Rosen Law Firm Reminds Seattle Genetics Inc. Investors of Important Deadline in Class Action - SGEN

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Seattle Genetics Inc. securities (NASDAQ:SGEN) from October 27, 2016 through December 23, 2016, inclusive (the "Class Period") of...

SGEN : 65.68 (+0.27%)
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data

Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.

CELG : 119.44 (-1.42%)
INCY : 122.36 (+1.55%)
GILD : 69.29 (-0.80%)
ACOR : 25.30 (unch)
SGEN : 65.68 (+0.27%)
REGN : 371.61 (+0.12%)
BIIB : 286.90 (-0.71%)
SGEN SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 14, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. ("Seattle Genetics" or the "Company") (NASDAQ:...

SGEN : 65.68 (+0.27%)
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western...

SGEN : 65.68 (+0.27%)
SGEN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Seattle Genetics Inc. and a Lead Plaintiff Deadline of March 13, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased Seattle Genetics...

SGEN : 65.68 (+0.27%)
Seattle Genetics to Present at Leerink Partners 6th Annual Global Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15 at 2:30pm Eastern...

SGEN : 65.68 (+0.27%)
Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss

Seattle Genetics, Inc (SGEN) reported a loss of 39 cents per share, wider than the Zacks Consensus Estimate of a loss of 34 cents and wider than the year-ago loss of 18 cents.

ENZ : 6.71 (-1.90%)
SGEN : 65.68 (+0.27%)
AGTC : 7.90 (-2.47%)
SNSS : 4.25 (unch)
Immunomedics Announces Postponement of 2016 Annual Meeting

Immunomedics, Inc. (NASDAQ: IMMU) ("Immunomedics" or "the Company") today announced it has postponed the Company's 2016 Annual Meeting of Stockholders previously scheduled for February 16, 2017. The Annual...

SGEN : 65.68 (+0.27%)
IMMU : 5.06 (-5.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability...

See More

Support & Resistance

2nd Resistance Point 66.60
1st Resistance Point 66.14
Last Price 65.68
1st Support Level 65.05
2nd Support Level 64.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.